Targeted Therapies in Epithelial Ovarian Cancer

Table 1

Clinical trials testing Bevacizumab in EOC.

	Type	Study’s Scope and Population	Intervention	Outcomes or Planned End Points
Published
Burger (2007) [14]	Phase II			CR: 3%
		62 patients with persistent or recurrent Ov or PP cancers		PR: 18%
				SD: 52%
		66% had received two prior chemotherapy regimens	Single-agent Bevacizumab	MPFS: 4.7
				6-mon PFS: 40%
		42% were platinum-resistant		MOS: 17
				GIP: 0%
				TED: 0%
Cannistra (∗) (2007) [15]	Phase II			CR: 0%
		44 patients with recurrent Ov or PP cancers		PR: 16%
		48% had received three prior chemotherapy regimens	Single-agent Bevacizumab	SD: Not reported
				MPFS: 4.4
		84% were platinum-resistant		MOS: 10.7
				GIP: 11%
				TED: 7%
Micha (2007) [16]	Phase II			CR:30%
		Adjuvant treatment in front-line	Carboplatin + Paclitaxel + Bevacizumab	PR:50%
		20 patients stage III Ov, PP, or FT cancers		SD: 5%
		85% optimally cytoreduced		TED: 10% (∗∗)
				GIP: 0%
Garcia (2008) [17]	Phase II			CR: 0%
				PR: 24%
		70 patients with recurrent Ov or PP cancers	Metronomic Cyclophosphamide + Bevacizumab	SD: 63%
		Median n of prior chemotherapy regimens: 2		MOS: 17
		40% were platinum-resistant		MPFS: 7
				TED: 4%
				GIP: 4%
Ongoing
TEACO	Phase II			1-year PFS
		Adjuvant treatment in front-line	Oxaliplatin + Docetaxel + Bevacizumab (both first line and maintenance)	Safety
		Stage IB-IV Ov, PP, or FT cancers		RR
		Either optimally or suboptimally cytoreduced		PFS
				OS
GOG 218	Phase III			PFS (primary)
		Adjuvant treatment in front-line	Carboplatin + Paclitaxel with or without Bevacizumab, either short-term or extended (maintenance)	OS
		Stage III-IV Ov or PP cancers		RR
		Either optimally or suboptimally cytoreduced		Toxicity
				QoL
				Translational objectives
ICON 7	Phase III	Adjuvant treatment in front-line		PFS (primary)
		High-risk early stage (I-IIA, clear cell or grade 3) or advanced stage (IIB or greater), either optimally or suboptimally cytoreduced Ov, PP, or FT cancers	Carboplatin + Paclitaxel with or without extended Bevacizumab	QoL
				Cost effectiveness
GOG 213	Phase III	Platinum-sensitive recurrent Ov, PP, or FT cancers	Carboplatin + Taxane with or without Bevacizumab with or without Secondary cytoreduction	OS (primary)
				PFS
				Toxicity
OCEANS (AVF4095g)	Phase III	Platinum-sensitive recurrent Ov, PP, or FT cancers	Carboplatin + Gemcitabine with or without both short-and long-term (manitenance) Bevacizumab	PFS
				OS
				RR
				Safety profile of the combination

Ov: Ovarian; PP: Primary peritoneal; FT: Fallopian Tube
RR: Response rate; CR: Complete response; PR: Partial response; SD: Stable disease
TED: Thromboembolic disease (either arterial or venous); GIP: Gastrointestinal perforation
MPFS: Median progression-free survival (months); MOS: Median overall survival (months);
QoL: Quality of life
(∗) Study stopped prematurely due to the high rate of severe complications (i.e., GIP)
(∗∗) TED cases were not directly attributed to bevacizumab.